 | |
- close
- close
Globe Newswire
Jan 28
Comment
SAN DIEGO, Jan. 28, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company has completed enrollment of the planned 375 subjects in its multinational Phase 3 trial of Allovectin-7® in patients with metastatic
Globe Newswire
Jan 26
Comment
WASHINGTON, Jan. 26, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company will present an overview of its DNA vaccine and adjuvant technologies and an update on its clinical-stage vaccine development programs at
Globe Newswire
Jan 14
Comment
SAN DIEGO, Jan. 14, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the appointment of Richard T. Kenney, M.D., as Vice President, Clinical Development. Prior to joining Vical, Dr. Kenney held key positions in influenza and
FierceBiotech
Jan 12
Comment
Vical's Japanese partner AnGes MG got a special protocol assessment approval from U.S. health regulators for a late-stage clinical trial of Collategene to treat peripheral arterial disease. The SPA provides a company with a written agreement that...
Globe Newswire
Jan 12
Comment
SAN DIEGO, Jan. 12, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company's licensee, AnGes MG, Inc., reported approval by the U.S. Food and Drug Administration (FDA) of the Special Protocol Assessment (SPA)
Globe Newswire
Jan 11
Comment
SAN DIEGO, Jan. 11, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the U.S. Department of Agriculture (USDA) has granted the company's licensee Merial Limited, the animal health subsidiary of sanofi-aventis, full
Globe Newswire
Jan 8
Comment
SAN DIEGO, Jan. 8, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that it has secured an issuer managed equity facility under which it may sell up to $25 million of its registered common stock to Azimuth Opportunity, Ltd.
StreetInsider.com
Jan 7
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Vical+%28VICL%29+Announces+that+In+Vivo+Testing+of+Vaxfactin+Shows+Increase+in+Antibody+and+T-Cell+Responses/5229428.html for the full story.
Globe Newswire
Jan 7
Comment
SAN DIEGO, Jan. 7, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that systematic in vivo testing of the company's Vaxfectin(R) adjuvant shows that it increased antibody and T-cell responses primarily by stimulating the
Stock Blog Hub
Dec 31
Comment
Vical Inc. (VICL) announced recently that its cancer drug candidate Allovectin-7 has received a positive opinion from an independent safety review board. The board recommended the continuation of the late-stage study of Allovectin-7.
The study...
Suggest other news sources for this topic
Thank you for your suggestion
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
VICL AT A GLANCE
References
| ||||||
|
|
